SCHEMBL5360086

SCHEMBL5360086

CC(C)(C)[Si](C)(C)Oc1ccc([C@H]2CC[C@H](NS(=O)(=O)c3c(F)c(F)c(F)c(F)c3F)CC2)c(O[Si](C)(C)C(C)(C)C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.34
PKM P14618 1/20 0.34
PKLR P30613 1/20 0.34
DRD2 P14416 8/20 0.34
ADRA1D P25100 8/20 0.34
ADRA1A P35348 8/20 0.34
ADRA1B P35368 8/20 0.34
BRD4 O60885 1/20 0.33
BRD2 P25440 1/20 0.33
BRD3 Q15059 1/20 0.33
MAPT P10636 1/20 0.33
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA9 Q16790 2/20 0.33
KMT2A Q03164 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5360089 1.00 L3MBTL1 (0.34) L3MBTL1PKMPKLRDRD2ADRA1D
SCHEMBL5363841 0.87 HTR1A (0.43) DRD2ADRA1DADRA1AADRA1BKMT2A
SCHEMBL5363835 0.87 HTR1A (0.43) DRD2ADRA1DADRA1AADRA1BKMT2A
SCHEMBL5364491 0.85 DPP4 (0.41) L3MBTL1DRD2ADRA1DADRA1AADRA1B
SCHEMBL5364485 0.85 DPP4 (0.41) L3MBTL1DRD2ADRA1DADRA1AADRA1B
SCHEMBL6433894 0.85 PGR (0.37) L3MBTL1DRD2BRD4BRD2BRD3
SCHEMBL6485691 0.85 PGR (0.37) L3MBTL1DRD2BRD4BRD2BRD3
SCHEMBL6486732 0.85 PGR (0.37) L3MBTL1DRD2BRD4BRD2BRD3
SCHEMBL5363019 0.84 HTR1A (0.42) DRD2ADRA1DADRA1AADRA1BBRD4
SCHEMBL5356423 0.84 HTR1A (0.42) DRD2ADRA1DADRA1AADRA1BBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7282592-B2 Resorcinol derivatives WARNER-LAMBERT COMPANY (US) 2007-10-16 US disclosed
US-7173052-B2 Resorcinol derivatives PFIZER INC. (US) 2007-02-06 US disclosed
US-20050282899-A1 Resorcinol for lightening skin removing color BRADLEY STUART E 2005-12-22 US disclosed
US-6852747-B2 Resorcinol derivatives PFIZER INC. (US) 2005-02-08 US disclosed
US-20030180236-A1 Resorcinol derivatives PFIZER PRODUCTS, INC. 2003-09-25 US disclosed
US-6590105-B2 For skin lightening or depigmentation; works by inhibiting tyrosinase in humans; kits WARNER-LAMBERT COMPANY 2003-07-08 US disclosed
US-20020114770-A1 Resorcinol derivatives PFIZER INC. 2002-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030180236-A1 Resorcinol derivatives LRAT, NQO1, ALDH1A2 L3MBTL1 3347/4885PKM 4169/4885PKLR 3179/4885
US-20050282899-A1 Resorcinol for lightening skin removing color RBP4, NQO1, ALDH1A2 L3MBTL1 2322/4885PKM 3678/4885PKLR 1970/4885
US-20020114770-A1 Resorcinol derivatives LRAT, NQO1, ALDH1A2 L3MBTL1 3347/4885PKM 4169/4885PKLR 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.